Singapore, May 3 -- Japan-based Meiji Seika Pharma Co. has announced that KM Biologics Co., a group company of Meiji Seika Pharma, has entered into a technology collaboration with Serum Institute of India Private Limited (SII), a Cyrus Poonawalla group company and the world's largest vaccine manufacturer, for the development and manufacturing of a Japanese encephalitis vaccine, and has achieved the first milestone under this collaboration.

This collaboration has been carried out based on a technology transfer agreement between KM Biologics and SII for the development and manufacturing of a Japanese encephalitis vaccine.

With the achievement of this milestone, SII will initiate development activities in India for the Japanese encephaliti...